SCHEMBL22855464

SCHEMBL22855464

CC(=O)N[C@H]1[C@H](OCC(=O)NCCCNC(=O)OC[C@H](O)CO)O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.46
▸ LMNA P02545 3/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ CYP3A4 P08684 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.40
▸ CYP2D6 P10635 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CA2 P00918 10/20 0.35
▸ MMP12 P39900 2/20 0.35
▸ CA9 Q16790 9/20 0.35
▸ CA12 O43570 8/20 0.35
▸ CA1 P00915 8/20 0.35
▸ TGM2 P21980 1/20 0.34
▸ MMP9 P14780 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22855538 0.90 POLB (0.41) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL22855285 0.89 CYP3A4 (0.49) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL22855693 0.89 CYP3A4 (0.49) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL22855470 0.89 CYP3A4 (0.49) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL22855275 0.86 CYP3A4 (0.46) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL22830108 0.85 CA2 (0.41) POLBLMNAALDH1A1CYP2D6THRB
SCHEMBL22886763 0.85 CYP3A4 (0.47) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL24699710 0.85 CYP3A4 (0.50) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL22855452 0.85 POLB (0.48) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL22886721 0.85 POLB (0.48) POLBLMNAKMT2AALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3763815-A1 THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA Daiichi Sankyo Company, Limited (JP) 2021-01-13 — — EP disclosed
US-20200407394-A1 THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407394-A1 THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA G6PC1, GAA, GBA3 POLB 242/4885LMNA 241/4885KMT2A 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback